Patented design for all pen injector applications
Compatible with insulin and other formulations including hormones, Terumo’s unique asymmetric tip is designed with the aim to reduce pain during insertion by cutting the skin on entry rather than piercing it.
Designed and engineered for subcutaneous injections, Nanopass™ 32.5G Needle for Pen Injectors offer the quality and supply reliability drug developers need to meet drug delivery challenges and product commercialization goals. By offering needle lengths of 4mm, 6mm and 8mm, Terumo strives to cover all patient groups.
Patient comfort in mind
- Asymmetric needle tip reduces skin trauma by cutting, not piercing skin on penetration2
- Smaller overall diameter compared to standard 32G
Engineered for automated environments
- Individually packed and sealed in an ergonomic plastic case for automated assembly and easier patient handling
- Each length color-coded on the unit pack for easy identification
Regulatory and Quality Aspects
- Irradiation to a Sterile Assurance Level at least 10-6
- In compliance with applicable ISO standards and Pharmacopoeia
CE certified: CE 0197
Certifying (Notified) Body: TÜV Rheinland LGA Products GmbH, Germany
![]()
- Proven track record of reliable supply assured by global operating company
General specifications
Nanopass™ 32.5G Needle for Pen Injectors are intended for use with a pen injector for subcutaneous applications of drugs (ex. insulin and human growth hormone).
|
Specifications Nanopass™ 32.5G |
|
|
|
|
Needle length | 4 mm | 6 mm | 8 mm |
|
Needle diameter | (Ø 0.22 mm) | (Ø 0.22 mm) | (Ø 0.22 mm) |
|
Package | 100 pcs
| 100 pcs | 100 pcs
|
Global Solutions
Nanopass™ 32.5G Needle for Pen Injectors solutions are available to drug product manufacturers globally. For more information about product availability, specifications, and applicable standards, download our data sheet or contact your Terumo representative today.
